Arava (Leflunomide)

Arava (Leflunomide): Comprehensive Guide for Australian Patients

1. Basic Product Information

2. Mechanism of Action

For Patients: Arava (leflunomide) works by reducing inflammation in your body. It calms the overactive immune system that causes long-term (chronic) conditions like rheumatoid arthritis. By controlling inflammation, it helps ease joint pain and swelling, making movement easier.

For Specialists: Leflunomide is an isoxazole derivative that selectively and reversibly inhibits dihydroorotate dehydrogenase, the rate-limiting enzyme in pyrimidine synthesis. This action arrests lymphocyte proliferation and reduces autoantibody production, contributing to its immunomodulatory and anti-inflammatory effects.

3. Pharmacokinetics

• Absorption: Leflunomide is well-absorbed when taken orally, with bioavailability above 80%.
• Metabolism: Rapidly converted in the body to its active metabolite A771726 in the liver.
• Elimination: Primarily via the urine and faeces; enters enterohepatic circulation, extending its activity.
• Onset of Action: Symptom improvement typically occurs within 4–6 weeks, with maximum benefits by 3–6 months.
• Half-life: Long, around 2 weeks, which allows for once daily dosing but also necessitates caution if urgent discontinuation is needed.

4. Use in Everyday Life & Best Practices

Typical Dosing:

• Most adult patients with rheumatoid arthritis start on 10 mg or 20 mg once daily, depending on tolerance and clinical judgment.
• Some protocols use a loading dose (100 mg daily for 3 days), but this is less common in Australia due to increased risk of side effects.
• Tablets should be taken consistently at the same time each day for best results.

1. Swallow the tablet whole with water; do not crush or chew.
2. Take daily as prescribed—missing doses can reduce effectiveness.
3. Routine blood tests are needed (see below) to monitor your response and safety.

5. Dosing in the Morning vs Evening

6. Taking with Food or on an Empty Stomach

• Can be taken with or without food. Food does not significantly affect leflunomide absorption.
• Some patients find it gentler on the stomach if taken after a meal, especially at the start.
• Australian Dietary Habits: Common Australian meals (toast, cereal, coffee, fruit) are compatible with leflunomide. No need to adjust your usual diet unless specifically directed by your doctor.

7. Interaction Warnings

Always check with your doctor or pharmacist before starting new medicines or supplements while taking leflunomide.

8. Indications (Uses)

9. Dosing According to Clinical Indication

10. Safety Profile & Side Effects

Most patients take leflunomide without major problems. However, side effects can occur and regular monitoring is essential. Let your doctor know if you have any concerns.

11. Guidelines for Proper Use (Australia Focus)

• Follow your doctor's instructions and pharmacy label exactly.
• Blood tests (liver function, blood count) are required before starting and during treatment—track appointment dates.
• If you develop a fever, sore throat, unexplained bleeding/bruising, cough or difficulty breathing, seek medical advice promptly.
• Women of childbearing age must use reliable contraception—do not use leflunomide while pregnant or breastfeeding.
• Leflunomide can stay in the body for months; special "washout" procedures (with cholestyramine) are available if stopping due to side effects or pregnancy plans.
• Discuss vaccinations with your GP—live vaccines should be avoided while on leflunomide.
• Store tablets in a cool, dry place, out of reach of children.

12. Alternative Treatment Options

• Methotrexate: Also a first-line DMARD (disease-modifying anti-rheumatic drug). Well-established, may be combined with leflunomide in selected cases. Requires folic acid supplementation and close monitoring.
• Sulfasalazine: Suitable for mild to moderate disease. Lower risk of liver side effects but may cause gastrointestinal upset.
• Hydroxychloroquine: Mild immunomodulator, more favourable side effect profile, but less effective alone for severe arthritis.
• Biological agents (e.g., etanercept, adalimumab): Used if other therapies fail or are not tolerated. More expensive and require injections; strict PBS criteria apply.
• Tofacitinib/Baricitinib: Newer oral therapies (JAK inhibitors), usually considered after other DMARDs.

The PBS (Australia) reimburses most standard DMARDs and biologics for eligible patients with rheumatological diseases. These decisions are made case-by-case based on your condition and treatment response.

13. Legal, Registration, and Reimbursement Status in Australia

• Registration: Registered with the Therapeutic Goods Administration (TGA) for use in autoimmune arthritis in adults.
• Legal Status: Prescription Medicine (Schedule 4).
• Reimbursement: Available on the PBS (Pharmaceutical Benefits Scheme) for rheumatoid arthritis and psoriatic arthritis.
• Supply: Widely available through community and hospital pharmacies with valid prescription; repeats as per PBS criteria.
• Authority Required: (Section 85) for PBS subsidy—your prescriber will manage this paperwork.

14. Latest Research & Clinical Guidance (2022–2025)

Recent Australian and international guidelines, including the Australian Rheumatology Association Consensus (2022), confirm leflunomide as an effective and affordable first- or second-line disease-modifying agent for rheumatoid arthritis and psoriatic arthritis. Recent studies (2022–2024, e.g., Ann Rheum Dis) highlight its ongoing role, particularly for those with intolerance to methotrexate.

• The safety profile is well established; combination with methotrexate is possible but increases monitoring needs.
• No new significant signals of long-term risk have emerged between 2022–2025; liver safety and birth defect avoidance remain primary concerns.
• New biosimilar options may increase accessibility and reduce costs for the Australian public health system.

15. Availability & Delivery (Australia)

*Indicative price as of 2024. Actual patient charge may vary depending on individual PBS status and pharmacy.

16. Frequently Asked Questions (FAQ)

1. How long will I need to take leflunomide?
This is usually a long-term (maintenance) medicine for chronic conditions such as rheumatoid arthritis or psoriatic arthritis. Your specialist will review your need for ongoing treatment at regular intervals.

2. Can I drink alcohol while taking leflunomide?
It is safest to avoid alcohol, or keep intake minimal, while on leflunomide due to the risk of liver injury. Discuss your personal situation with your doctor.

3. Can I become pregnant while taking leflunomide?
No. Leflunomide can harm an unborn child. Women of childbearing age must use effective contraception during, and for some time after, treatment. A “washout” procedure is required if pregnancy is planned.

4. What should I do if I miss a dose?
Take the missed dose as soon as you remember, unless it is almost time for your next dose. Do not double up. If unsure, ask your pharmacist or doctor.

5. How often do I need blood tests?
Before starting, then usually every 2–4 weeks for the first few months, then every 2–3 months once stable. Your doctor may adjust the frequency based on your personal health.

This content is for informational purposes only and does not substitute for medical advice from your Australian healthcare provider. For further questions, consult your GP, specialist, or community pharmacist.